Stage 3 Mesothelioma

Stage 3 Mesothelioma

Stage 3 Mesothelioma Overview
Staging System	IASLC TNM 8th Edition (2018)
Stage IIIA	T1-3 N1 M0 or T3 N0 M0
Stage IIIB	T1-3 N2 M0 or T4 any N M0
Median Survival	~16 months (with treatment)
1-Year Survival	62%
2-Year Survival	29%
5-Year Survival	6%
First-Line Treatment	Nivolumab + ipilimumab (FDA-approved)
Surgery Candidacy	Select Stage IIIA only
Active Clinical Trials	93+ recruiting worldwide (2026)
Key First Step	Free legal case evaluation

Stage 3 mesothelioma represents locally advanced disease where the cancer has spread beyond the point of origin into nearby lymph nodes or adjacent structures, but has not metastasized to distant organs.[1] Under the IASLC TNM 8th Edition staging system, Stage III is divided into Stage IIIA and Stage IIIB based on the extent of tumor invasion and lymph node involvement.[2]

A Stage 3 diagnosis does not mean treatment options are exhausted. Immunotherapy has fundamentally changed the treatment landscape since 2020, and the 5-year update of the landmark CheckMate 743 trial confirms that 14% of patients receiving nivolumab plus ipilimumab are alive at 5 years — more than double the rate with chemotherapy alone.[3] For carefully selected Stage IIIA patients, multimodal treatment combining surgery with systemic therapy may extend survival further, though the role of surgery has become increasingly controversial following the MARS 2 trial results.[4]

Stage 3 pleural mesothelioma at a glance:

• Median survival is approximately 16 months with active treatment, compared to 21 months for Stage I and 12 months for Stage IV[5]
• Immunotherapy is now the standard first-line treatment — nivolumab plus ipilimumab achieved median overall survival of 18.1 months across all stages in CheckMate 743[3]
• Stage IIIA may still be surgically operable in select patients with epithelioid histology and good performance status at high-volume centers[6]
• Stage IIIB is generally treated without surgery using systemic immunotherapy, chemotherapy, or clinical trial enrollment[4]
• Cell type dramatically affects prognosis — epithelioid Stage III patients have median survival of approximately 22 months versus 6 months for sarcomatoid[7]
• More than 93 clinical trials are actively recruiting mesothelioma patients worldwide as of 2026, including 5 CAR-T cell therapy trials[8]
• Peritoneal Stage 3 patients treated with CRS-HIPEC at high-volume centers achieve markedly better outcomes, with median survival of 38 to 67 months[9]
• Financial compensation is available through asbestos trust funds, lawsuits, and VA benefits — most can be pursued simultaneously[10]

---

What Is Stage 3 Mesothelioma?

Stage 3 mesothelioma is classified using the IASLC TNM 8th Edition staging system, adopted in 2018. The TNM system evaluates three factors: the extent of the primary Tumor, spread to regional lymph Nodes, and presence of distant Metastasis.[2] Stage III indicates locally advanced disease — the tumor has grown into nearby structures or spread to regional lymph nodes, but no distant metastases are present (M0).[2]

Stage IIIA vs. Stage IIIB

Stage III is subdivided into two categories with different prognoses and treatment implications:

Substage	TNM Criteria	What This Means
Stage IIIA	T1-3 N1 M0, or T3 N0 M0	Tumor involves the pleura with limited chest wall or mediastinal invasion (T1-3) and has spread to ipsilateral (same-side) bronchopulmonary or hilar lymph nodes (N1). Also includes locally advanced tumors (T3) without lymph node involvement.[2]
Stage IIIB	T1-3 N2 M0, or T4 any N M0	Tumor has spread to contralateral mediastinal or supraclavicular lymph nodes (N2), or the primary tumor has invaded deeply into the chest wall, spine, heart muscle, or through the diaphragm into the peritoneum (T4).[2]

Key distinction: Stage IIIA may still be considered for surgical resection in select patients at experienced centers. Stage IIIB, with its deeper invasion or contralateral lymph node spread, is generally considered inoperable and treated with systemic therapy.[4][6]

T Descriptors Relevant to Stage III

• T3: Tumor involves at least one of the following — locally advanced but potentially resectable invasion into the endothoracic fascia, mediastinal fat, a solitary focus of chest wall invasion, or non-transmural pericardial involvement[2]
• T4: Tumor involves at least one of the following — diffuse or multifocal chest wall invasion, direct extension through the diaphragm into the peritoneum, direct invasion of mediastinal organs, direct extension to the contralateral pleura, or invasion into the spine, heart, or great vessels[2]

N Descriptors Relevant to Stage III

• N1: Ipsilateral bronchopulmonary, hilar, or mediastinal lymph nodes — cancer has spread to lymph nodes on the same side as the primary tumor[2]
• N2: Contralateral mediastinal, ipsilateral or contralateral supraclavicular lymph nodes — cancer has crossed to nodes on the opposite side or above the collarbone[2]

TNM 9th Edition (2025)

The IASLC released the TNM 9th Edition in 2025, which introduces Psum (pleural thickness summation) measurements as a new way to quantify tumor burden in pleural mesothelioma.[11] The N and M descriptors remain unchanged from the 8th Edition. The 9th Edition is not yet widely adopted in clinical practice or most published survival data, so this page references the 8th Edition unless otherwise noted.[11]

How Does Stage 3 Differ From Stage 2 and Stage 4?

Stage	Key Difference	Median OS	5-Year Survival
Stage I	Tumor confined to ipsilateral pleura, no lymph node involvement	~21 months	33%
Stage II	Tumor with limited local invasion, no lymph node involvement	~19 months	9%
Stage III	Lymph node involvement (N1-N2) or deep local invasion (T3-T4)	~16 months	6%
Stage IV	Distant metastasis (M1)	~12 months	4%

Stage III represents the threshold between potentially operable and definitively inoperable disease. While Stage II tumors may be surgically resectable in most cases, only carefully selected Stage IIIA patients with favorable features are considered for surgery in 2026.[5][6]

Learn more: Mesothelioma Diagnosis and Staging

---

What Are the Survival Statistics for Stage 3 Mesothelioma?

Survival statistics for Stage 3 pleural mesothelioma are drawn from large national databases including the National Cancer Database (NCDB) and SEER (Surveillance, Epidemiology, and End Results) registry. These population-level data include patients across all treatment modalities and time periods, meaning individual outcomes may differ significantly based on treatment, cell type, and overall health.[5]

Core Survival Data

Metric	Stage III Value	Source
Median Overall Survival	~16 months (with treatment)	NCDB/SEER compilation[5]
1-Year Survival Rate	62%	NCDB/SEER[5]
2-Year Survival Rate	29%	NCDB/SEER[5]
5-Year Survival Rate	6%	NCDB/SEER[5]
NCDB All-Comers Median OS	10.3 months (includes untreated)	NCDB[12]
Hazard Ratio vs. Stage I/II	1.49 (95% CI 1.18–1.89; p=0.001)	IASLC Staging Project[2]

Important: These figures include patients diagnosed before immunotherapy approval in 2020. Patients diagnosed in 2026 receiving modern immunotherapy may experience significantly better outcomes than these historical averages suggest.

How Cell Type Affects Stage 3 Prognosis

The histologic subtype of mesothelioma is one of the strongest predictors of survival at every stage, including Stage III. Within Stage III, the difference between epithelioid and sarcomatoid disease is dramatic.[7]

Cell Type	Approximate Median OS	Characteristics
Epithelioid	~22 months	Most common (60-70% of cases); most treatable; best response to surgery and immunotherapy[7]
Biphasic	~12 months	Mixed epithelioid and sarcomatoid cells; prognosis depends on the ratio of each component[7]
Sarcomatoid	~6 months	Most aggressive; poorest response to treatment; benefits most from immunotherapy over chemotherapy[7][3]

The landmark CheckMate 743 trial demonstrated particularly striking results for non-epithelioid patients: the 5-year overall survival rate was 12% with nivolumab plus ipilimumab versus just 1% with chemotherapy (HR 0.48), representing a historically unprecedented benefit for this aggressive subtype.[3]

Prognostic Factors Beyond Stage and Cell Type

Multiple validated scoring systems identify additional factors that influence Stage 3 prognosis:[13][14]

• Performance status (ECOG): Patients with ECOG 0–1 (active, ambulatory) have significantly better outcomes than those with ECOG 2+ across all scoring systems[13]
• Gender: Female patients have a survival advantage — HR 0.78 versus male patients in large SEER analyses (5-year: 13.4% vs. 4.5%)[15]
• Age: Younger patients (<50 years) have 5-year survival rates of approximately 39%, compared to 4.5% for patients over 75[15]
• Neutrophil-to-lymphocyte ratio (NLR): NLR ≥5 carries an adjusted HR of 2.7 (95% CI 1.8–3.9); 1-year survival drops from 60% to 26%[14]
• Weight loss: Present in the strongest prognostic model (Brims decision tree); patients without weight loss and with favorable blood markers can achieve 18-month survival rates of 87%[14]
• BAP1 germline mutation: Carriers exhibit 7-fold improved long-term survival with a median of approximately 5 years — a dramatic exception to typical Stage III prognosis[16]

Learn more: Survival Rates and Treatment Options

---

How Has Treatment Changed Stage 3 Outcomes?

The treatment landscape for Stage 3 mesothelioma has undergone two seismic shifts since 2020, fundamentally altering what this diagnosis means for patients.

The Immunotherapy Revolution (2020–Present)

Before October 2020, the only FDA-approved first-line systemic treatment for unresectable pleural mesothelioma was pemetrexed combined with cisplatin, approved in 2004. This chemotherapy regimen offered a median overall survival of approximately 12 months and a response rate of 41%.[17]

The FDA approval of nivolumab plus ipilimumab in October 2020, based on the CheckMate 743 trial, represented the first new systemic therapy approval for mesothelioma in 16 years. The February 2026 five-year update published in the Journal of Clinical Oncology confirmed durable long-term benefit:[3]

Outcome	Nivolumab + Ipilimumab	Chemotherapy
Median Overall Survival	18.1 months	14.1 months
2-Year Overall Survival	41%	27%
5-Year Overall Survival	14%	6%
5-Year Progression-Free Survival	8%	0%
Ongoing Response at 5 Years	17% of responders	0%
Non-Epithelioid 5-Year OS	12%	1%
Hazard Ratio (overall)	0.74 (95% CI 0.62–0.88)
Hazard Ratio (non-epithelioid)	0.48 (95% CI 0.33–0.68)

The 5-year data are particularly notable because no chemotherapy patients had ongoing responses at 5 years, while 17% of immunotherapy responders did. This suggests that a subset of patients may achieve long-term disease control — something not previously possible with chemotherapy.[3]

In September 2024, pembrolizumab combined with platinum-pemetrexed chemotherapy received FDA approval based on the IND.227 trial (n=440), offering a second immunotherapy-based first-line option with a median OS of 17.3 months and a near-doubling of the response rate (62% vs. 38%).[18]

The MARS 2 Trial: Surgery Under Scrutiny (2024)

The MARS 2 trial, published in The Lancet Respiratory Medicine in 2024, was the first randomized controlled trial comparing surgery plus chemotherapy to chemotherapy alone for resectable pleural mesothelioma. The results challenged decades of surgical practice:[4]

• Surgery arm median OS: 19.3 months versus 24.8 months for chemotherapy alone
• Surgery was associated with 28% increased mortality risk in the first 42 months (HR 1.28)
• The surgery group experienced 3.36-fold more serious adverse events
• Quality of life was worse in the surgery arm across multiple domains

These findings have led most major guidelines to shift away from routine surgical resection as a standard of care. However, the trial specifically evaluated extended pleurectomy/decortication (EPD) across multiple UK hospitals with varying surgical volumes. A February 2026 Mount Sinai study (n=71) demonstrated 0% 30-day mortality with standard P/D in carefully selected patients at an expert center, suggesting that outcomes depend heavily on patient selection and surgical expertise.[19]

Learn more: Mesothelioma Surgery Overview • CheckMate 743 Trial

---

What Treatment Options Are Available for Stage 3 Patients?

Treatment selection for Stage 3 mesothelioma depends on the substage (IIIA vs. IIIB), cell type, performance status, and patient preferences. A multidisciplinary tumor board at an experienced mesothelioma center is essential for determining the optimal approach.[6]

First-Line Immunotherapy

Nivolumab plus ipilimumab (CheckMate 743) is the current standard first-line treatment for unresectable pleural mesothelioma, including most Stage III patients.[3] Treatment consists of nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks, continued for up to 2 years unless disease progression or unacceptable toxicity occurs.[3]

Pembrolizumab plus platinum-pemetrexed (IND.227) is an approved alternative offering the combination of immunotherapy and chemotherapy. This may be preferred for epithelioid patients, where the chemotherapy component adds response rate benefit (62% vs. 38%).[18]

Key consideration: For non-epithelioid Stage III disease (sarcomatoid or biphasic), nivolumab plus ipilimumab is strongly preferred — the 5-year survival advantage over chemotherapy (12% vs. 1%) is the most dramatic benefit seen in any mesothelioma subgroup.[3]

Chemotherapy

Pemetrexed plus cisplatin (or carboplatin) remains the standard alternative for patients who cannot receive immunotherapy due to:[17]

• Active autoimmune disease
• Organ transplant history
• Requirement for high-dose corticosteroids
• Other immunotherapy contraindications

Bevacizumab may be added to pemetrexed-platinum based on the MAPS trial, which showed improved median OS from 16.1 to 18.8 months with the addition of the anti-angiogenic agent.[17]

Tumor Treating Fields (TTFields)

Optune Lua (NovoTTF-100L) is an FDA-approved wearable device that delivers alternating electric fields to disrupt cancer cell division. In the STELLAR trial (n=80), TTFields combined with pemetrexed-based chemotherapy achieved a median OS of 18.2 months and a disease control rate of 97%.[20] TTFields is prescribed alongside first-line chemotherapy for patients with unresectable pleural mesothelioma.

Surgery: When It Is Still Considered

Following the MARS 2 trial, surgery is no longer routinely recommended for most Stage III patients. However, select Stage IIIA patients may still be considered for surgical resection when all of the following criteria are met:[4][6][19]

• Epithelioid histology (confirmed on biopsy)
• ECOG performance status 0–1
• No N2 lymph node involvement (confirmed by mediastinoscopy or PET/CT)
• Treatment at a high-volume mesothelioma center with proven surgical outcomes
• Patient is evaluated and selected by a multidisciplinary tumor board

When surgery is performed, pleurectomy/decortication (P/D) — a lung-sparing procedure — is strongly preferred over extrapleural pneumonectomy (EPP). The 663-patient multi-institutional analysis by Flores et al. demonstrated that EPP carried a 40% higher hazard of death than P/D.[21] NCDB data show that Stage III patients receiving both chemotherapy and surgery had a median OS of 21.7 months compared to 11.4 months with chemotherapy alone, though this reflects selection bias favoring healthier, more operable patients.[12]

Perioperative Immunotherapy

A Phase II trial published in Nature Medicine (September 2025) tested neoadjuvant nivolumab plus ipilimumab (3 cycles before surgery) in resectable pleural mesothelioma, achieving a median OS of 28.6 months. Circulating tumor DNA (ctDNA) clearance after neoadjuvant therapy predicted significantly longer event-free and overall survival, establishing ctDNA as a potential biomarker for guiding surgical decisions.[22]

Second-Line Treatment Options

When first-line treatment fails, several second-line options are available based on the 2025 ASCO Guideline Update:[23]

After First-Line Chemotherapy	After First-Line Immunotherapy
Nivolumab ± ipilimumab Gemcitabine + ramucirumab (RAMES trial: median OS 13.8 months vs. 7.5 months)[23] Oral vinorelbine (VIM trial: median PFS 4.2 months vs. 2.8 months)[23] Pemetrexed rechallenge (if good initial response)	Pemetrexed + platinum ± bevacizumab (Japanese study: median OS 17.1 months)[23]

Learn more: Chemotherapy for Mesothelioma • Immunotherapy for Mesothelioma • Radiation Therapy

---

What Clinical Trials Are Open for Stage 3 Mesothelioma?

As of 2026, the mesothelioma clinical trial pipeline is the most diversified in the disease's history, with 93 actively recruiting trials worldwide — 52 in the United States.[8] Stage 3 patients are eligible for the majority of these trials. Key categories include:

Phase III Trials Currently Enrolling

Trial	Treatment	Target Enrollment	NCT Number
eVOLVE-Meso	Volrustomig (bispecific PD-1/CTLA-4) + chemo vs. investigator's choice	825 patients	NCT06097728
HIT-Meso	Proton beam therapy vs. active surveillance	148 patients	NCT05655078

Targeted Therapy Trials

• MRTX1719 (NCT05245500) — First-in-class PRMT5 inhibitor for MTAP-deleted tumors (~25% of mesothelioma patients)[8]
• SW-682 — YAP/TEAD pathway inhibitor for NF2-mutated tumors (~40% of mesothelioma patients)[8]
• VT3989 — TEAD inhibitor with approximately 20% objective response rate in pretreated patients[8]
• Tazemetostat (NCT02860286) — EZH2 inhibitor for BAP1-loss mesothelioma[8]
• Olaparib (NCT04515836) — PARP inhibitor for homologous recombination-deficient mesothelioma[8]

CAR-T Cell Therapy Trials

Five active CAR-T trials are recruiting mesothelioma patients at major centers:[8]

• MSK M28z1XXPD1DNR (NCT04577326) — Mesothelin-targeted CAR-T with built-in PD-1 resistance; prior phase showed 72% ORR in mesothelioma when combined with pembrolizumab (Memorial Sloan Kettering)[8]
• TNhYP218 — NCI 100-patient trial using next-generation T naïve/stem cell memory CAR-T cells (NIH Clinical Center)[8]
• EVEREST-2 A2B694 (NCT06051695) — Logic-gated CAR-T that selectively kills tumor cells while sparing normal tissue[8]
• SynKIR-110 — Novel KIR-CAR architecture targeting mesothelin (MD Anderson, Penn, UW-Madison)[8]
• CAR.70-IL15 NK cells (NCT05703854) — Off-the-shelf cord blood NK cell therapy targeting CD70 (MD Anderson)[8]

Cancer Vaccines

• UV1 telomerase vaccine — FDA Fast Track designated (February 2024); Phase II results showed 31% response rate when combined with immunotherapy versus 16% with immunotherapy alone, with a median OS improvement to 15.4 months versus 11 months[8]

How to Find Clinical Trials

Patients can search for trials at ClinicalTrials.gov using the search term "mesothelioma." Key eligibility factors include performance status (most trials require ECOG 0–1), prior treatment history, histology, and in some cases biomarker status (BAP1, MTAP, mesothelin expression).[8]

Learn more: Mesothelioma Clinical Trials

---

Where Should Stage 3 Patients Seek Treatment?

Mesothelioma treatment outcomes vary significantly based on where patients receive care. The volume–outcome relationship in mesothelioma surgery is well documented: a National Cancer Database analysis found that high-volume facilities achieved 90-day mortality of 10.0% versus 14.6% at lower-volume facilities, and median overall survival of 18 versus 15 months.[24]

High-Volume Mesothelioma Centers

The following NCI-designated comprehensive cancer centers and specialized mesothelioma programs have published peer-reviewed institutional series and treat the highest volumes of mesothelioma patients in the United States:[24]

• Brigham and Women's Hospital / Dana-Farber Cancer Institute (Boston, MA) — International Mesothelioma Program, led by Dr. Raphael Bueno; the largest mesothelioma program in the world[24]
• Memorial Sloan Kettering Cancer Center (New York, NY) — Highest referral volume in the U.S.; leader in mesothelin-targeted CAR-T research under Dr. Prasad Adusumilli[24]
• Mount Sinai / Tisch Cancer Center (New York, NY) — Led by Dr. Raja Flores; published 2026 series showing 0% 30-day mortality with P/D in selected patients[19]
• University of Pennsylvania / University of Maryland — Dr. Joseph Friedberg's photodynamic therapy + P/D program; achieved median OS of 36 months in advanced-stage patients[24]
• MD Anderson Cancer Center (Houston, TX) — NCI-designated comprehensive cancer center with active mesothelioma surgery and immunotherapy programs[24]
• H. Lee Moffitt Cancer Center (Tampa, FL) — NCI-designated center with active mesothelioma immunotherapy trials[24]

For peritoneal mesothelioma, specialized CRS-HIPEC programs include the Washington Cancer Institute (Dr. Paul Sugarbaker), Wake Forest Baptist Medical Center, and international centers such as the Istituto Nazionale dei Tumori in Milan.[25]

The Value of a Second Opinion

Given mesothelioma's rarity — approximately 3,000 diagnoses per year in the United States — many community oncologists encounter few or no cases during their career. A second opinion from a mesothelioma specialist can change the diagnosis, staging, and treatment plan. The Mount Sinai experience demonstrated that careful patient selection and surgical expertise at a high-volume center produce dramatically different outcomes than the general MARS 2 trial population.[19][24]

Learn more: Mesothelioma Treatment Centers

---

What About Peritoneal Stage 3 Mesothelioma?

Peritoneal mesothelioma — cancer of the lining of the abdomen — uses a different staging framework than pleural disease. While there is no universally adopted TNM staging system for peritoneal mesothelioma equivalent to the pleural system, advanced peritoneal disease is assessed primarily by the Peritoneal Cancer Index (PCI) score, which measures the extent of tumor distribution across 13 abdominal regions.[9]

CRS-HIPEC: The Standard of Care

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the most effective treatment available for operable peritoneal mesothelioma and achieves dramatically better outcomes than any pleural treatment:[9][25]

Metric	CRS-HIPEC Outcomes
Median Overall Survival	38–67 months (vs. ~12 months with systemic chemotherapy alone)
5-Year Survival (complete cytoreduction)	47–52% at high-volume centers
5-Year Survival (French national study, 2026)	84.6% among upfront-resectable patients achieving complete cytoreduction
Key Prognostic Factor	Completeness of cytoreduction (CC-0 score): median OS 104 months vs. 2.7 months for CC-2+

The 2026 French multicenter study — analyzing 924 peritoneal mesothelioma patients over 10 years — is among the most comprehensive population-level datasets for this disease, confirming that expert-center CRS-HIPEC achieves exceptional long-term survival for resectable patients.[25]

Patient Selection for CRS-HIPEC

Optimal candidates have:[9]

• PCI score ≤17
• Epithelioid histology
• ECOG performance status 0–1
• No extraperitoneal disease
• Adequate organ reserves for major surgery

Learn more: Peritoneal Mesothelioma

---

What Legal Rights Do Stage 3 Patients Have?

A Stage 3 mesothelioma diagnosis carries both medical urgency and legal significance. Because mesothelioma is caused almost exclusively by asbestos exposure, patients and their families may be entitled to substantial financial compensation through multiple pathways — most of which can be pursued simultaneously without reducing each other.[10]

Compensation Pathways

• Asbestos trust funds: More than 60 active trusts hold over $30 billion in reserved funds. Most mesothelioma patients qualify for 5 to 8 simultaneous trust fund claims, with combined average recovery of $300,000–$400,000. Trust fund claims are the fastest path to compensation, typically delivering payments within 2 to 6 months of filing.[10]

• Mesothelioma lawsuits: Personal injury claims can result in significant settlements or jury verdicts. Courts frequently grant expedited trial dates for mesothelioma plaintiffs — 85% of cases receive priority scheduling within 6 to 9 months. Combined average recovery across trust funds and litigation exceeds $1.4 million.[10]

• VA disability benefits: Veterans diagnosed with mesothelioma qualify for 100% VA disability rating — the highest tier — with monthly compensation of $3,938.58 as of 2026. Mesothelioma is a presumptive condition linked to military asbestos exposure, simplifying the claims process. Approximately 30–33% of all U.S. mesothelioma patients are veterans.[26]

• Workers' compensation: Patients with occupational asbestos exposure may file workers' compensation claims. Most states apply a discovery rule, meaning the statute of limitations begins at the date of diagnosis, not the date of exposure.[10]

Statute of Limitations

Filing deadlines vary by state and compensation type, ranging from 1 year in states like California and Tennessee to 6 years in Maine and North Dakota. Stage 3 patients should consult an asbestos attorney promptly after diagnosis to preserve all options.[10]

All mesothelioma attorneys work on a contingency fee basis — patients pay no upfront costs, and attorney fees are deducted only from successful recovery.[10]

Learn more: Immediate Financial Assistance • Asbestos Trust Funds • Veterans Benefits • Statute of Limitations by State

---

Frequently Asked Questions

What is the life expectancy for Stage 3 mesothelioma?

The median overall survival for Stage 3 pleural mesothelioma is approximately 16 months with active treatment. However, individual life expectancy varies significantly based on cell type (epithelioid ~22 months vs. sarcomatoid ~6 months), treatment received, performance status, and other prognostic factors. Patients treated with nivolumab plus ipilimumab in CheckMate 743 had a median OS of 18.1 months across all stages, with 14% alive at 5 years. BAP1 germline mutation carriers may achieve median survival of approximately 5 years.[3][5][7][16]

Can Stage 3 mesothelioma be cured?

There is currently no established cure for Stage 3 mesothelioma. However, long-term survival is possible. In the CheckMate 743 trial, 14% of patients receiving immunotherapy were alive at 5 years, and 17% of responders maintained ongoing responses at that point — suggesting durable disease control in a subset of patients. For peritoneal mesothelioma treated with CRS-HIPEC, 5-year survival rates reach 47–52% at high-volume centers, with the 2026 French national study reporting 84.6% 5-year survival in upfront-resectable patients achieving complete cytoreduction.[3][25]

What are the treatment options for Stage 3 mesothelioma?

Primary treatment options include: (1) nivolumab plus ipilimumab — the standard first-line immunotherapy; (2) pembrolizumab plus platinum-pemetrexed — an approved immunotherapy-chemotherapy combination; (3) pemetrexed plus cisplatin/carboplatin — standard chemotherapy for patients who cannot receive immunotherapy; (4) Tumor Treating Fields (Optune Lua) — an FDA-approved device used with chemotherapy; (5) surgery — considered only for select Stage IIIA patients at experienced centers; and (6) clinical trials — with over 93 actively recruiting trials as of 2026.[3][4][17][18][20]

Is Stage 3 mesothelioma operable?

Stage IIIA may be operable in carefully selected patients with epithelioid histology, good performance status (ECOG 0–1), and no N2 lymph node involvement, when treated at a high-volume mesothelioma center. Pleurectomy/decortication (P/D) is the preferred lung-sparing surgical approach. Stage IIIB is generally considered inoperable. The MARS 2 trial (2024) showed that extended P/D was associated with worse survival than chemotherapy alone, making patient selection and surgical expertise critical factors in the decision.[4][6][19]

How long do Stage 3 mesothelioma patients live with immunotherapy?

In the CheckMate 743 trial, patients receiving nivolumab plus ipilimumab had a median overall survival of 18.1 months across all stages. At 2 years, 41% were alive; at 5 years, 14% were alive. For non-epithelioid patients, the 5-year survival rate was 12% with immunotherapy versus just 1% with chemotherapy. These results include all stages, not Stage III specifically, as stage-specific immunotherapy survival data from clinical trials have not been separately published.[3]

What is Stage 3A vs. Stage 3B mesothelioma?

Stage IIIA involves tumor invading the pleura with spread to same-side (ipsilateral) lymph nodes (N1), or locally advanced tumors (T3) without lymph node spread. Stage IIIB involves deeper invasion (T4, such as into the spine, heart, or peritoneum) or spread to opposite-side (contralateral) or supraclavicular lymph nodes (N2). The key clinical distinction is that Stage IIIA may still be considered for surgery in selected patients, while Stage IIIB is generally treated with systemic therapy alone.[2]

Is Stage 3 mesothelioma terminal?

A Stage 3 diagnosis is serious, but it is not uniformly terminal. With modern immunotherapy, 14% of patients in the CheckMate 743 trial survived 5 years or longer. Individual prognosis depends on cell type, treatment response, overall health, and access to specialist care. Early integration of palliative care alongside disease-directed treatment has been shown to improve both quality of life and survival, and is recommended for all Stage 3 patients.[3][27]

What is the best treatment for Stage 3 pleural mesothelioma?

Current evidence supports nivolumab plus ipilimumab as the preferred first-line treatment for most Stage 3 pleural mesothelioma patients, based on the CheckMate 743 5-year data showing durable long-term benefit and a 14% 5-year survival rate. For epithelioid patients, pembrolizumab plus platinum-pemetrexed is an approved alternative with a near-doubling of response rate. For select Stage IIIA patients, multimodal therapy combining surgery with systemic treatment at a high-volume center may be considered. The best approach is determined by a multidisciplinary tumor board based on individual patient factors.[3][18][6]

Can Stage 3 mesothelioma patients qualify for clinical trials?

Yes. Most mesothelioma clinical trials accept patients with Stage III disease. Eligibility typically requires ECOG performance status 0–1, adequate organ function, and histologic confirmation. Some targeted therapy trials require specific biomarker testing (BAP1 loss, MTAP deletion, or mesothelin expression). The largest currently enrolling trial — eVOLVE-Meso (NCT06097728) — is recruiting 825 patients globally and accepts all histologies. Patients should ask their oncologist about trial eligibility or search ClinicalTrials.gov.[8]

What financial compensation is available for Stage 3 mesothelioma patients?

Stage 3 patients may be eligible for multiple simultaneous compensation sources: asbestos trust funds (combined average recovery $300,000–$400,000, payments within 2–6 months), personal injury lawsuits (combined average exceeding $1.4 million), VA disability benefits for veterans ($3,938.58/month at 100% rating), and workers' compensation. All mesothelioma attorneys work on contingency — patients pay no upfront costs. Filing promptly after diagnosis is important because statutes of limitations vary by state.[10][26]

---

Get Help

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice

If you or a loved one has been diagnosed with Stage 3 mesothelioma, an experienced asbestos attorney can evaluate your case at no cost and identify all compensation options that apply to your situation.

• Danziger & De Llano — Call (866) 222-9990 for a free consultation
• Mesothelioma Lawyers Near Me — Free case evaluation quiz
• Mesothelioma.net — Patient resources and treatment information
• Mesothelioma Lawyer Center — Legal resources and guidance

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

---

Related Pages

• Mesothelioma Diagnosis and Staging
• Survival Rates and Treatment Options
• CheckMate 743 Trial
• Immunotherapy for Mesothelioma
• Chemotherapy for Mesothelioma
• Mesothelioma Surgery Overview
• Radiation Therapy for Mesothelioma
• Mesothelioma Clinical Trials
• Mesothelioma Treatment Centers
• Peritoneal Mesothelioma
• Asbestos Trust Funds
• Veterans Benefits
• Immediate Financial Assistance
• Statute of Limitations by State